Microfragmented Adipose Tissue Injection (MFAT) May Be a Solution to the Rationing of Total Knee Replacement: A Prospective, Gender-Bias Mitigated, Reproducible Analysis at Two Years
Table 6
Patients grouped by age at time of treatment (baseline) with follow-up OKS at 3, 6, 12, and 24 months.
Gender
OKS period
Count
Mean
Median
SD
Data
Female
0
41
24.9
24.5
7.0
d1
Female
1
41
31.0
32.5
9.6
d1
Female
2
41
31.0
33.0
9.0
d1
Female
3
41
33.4
34.0
9.7
d1
Female
4
41
31.5
34.0
10.9
d1
Male
0
35
30.2
31.5
8.2
d1
Male
1
35
32.4
35.0
7.4
d1
Male
2
35
32.6
32.5
7.3
d1
Male
3
35
31.7
30.0
9.1
d1
Male
4
35
32.2
35.0
10.7
d1
Female
0
48
25.0
24.0
10.3
d2
Female
1
48
29.3
29.0
10.4
d2
Female
2
48
29.8
32.5
11.0
d2
Female
3
48
36.5
36.0
7.8
d2
Female
4
48
37.8
40.0
9.4
d2
Male
0
64
29.6
29.0
8.2
d2
Male
1
64
35.4
37.0
8.7
d2
Male
2
64
35.1
37.0
8.1
d2
Male
3
64
35.5
37.0
8.8
d2
Male
4
64
34.1
36.0
10.6
d2
Female
0
61
27.4
28.0
7.9
d3
Female
1
61
34.4
35.0
8.5
d3
Female
2
61
34.1
37.5
11.0
d3
Female
3
61
35.1
37.0
10.0
d3
Female
4
61
35.4
36.0
8.1
d3
Male
0
95
30.5
32.0
10.2
d3
Male
1
95
35.7
38.0
8.8
d3
Male
2
95
34.5
37.0
9.6
d3
Male
3
95
37.1
39.5
9.3
d3
Male
4
95
38.4
39.5
8.0
d3
OKS period: 0—baseline, 1—3 months postinjection, 2—6 months postinjection, 3—12 months postinjection, 4—24 months postinjection. Count: the number of patients in each group. Mean, median, and SD (standard deviation). Data: d1—age at time of treatment ≥75, d2—age at time of treatment , d3—age at time of treatment ≤65.
